1,2,4-三唑[4,3-b]吡嗪衍生物靶向急性髓系白血病:分子对接、动力学和ADMET方法。

In silico pharmacology Pub Date : 2025-09-17 eCollection Date: 2025-01-01 DOI:10.1007/s40203-025-00418-1
Vincent A Obakachi, Krishna K Govender, Penny P Govender
{"title":"1,2,4-三唑[4,3-b]吡嗪衍生物靶向急性髓系白血病:分子对接、动力学和ADMET方法。","authors":"Vincent A Obakachi, Krishna K Govender, Penny P Govender","doi":"10.1007/s40203-025-00418-1","DOIUrl":null,"url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) remains a critical therapeutic challenge, warranting the development of novel inhibitors targeting essential survival proteins such as Myeloid Cell Leukemia-1 (Mcl-1). In this purely computational study, a series of 1,2,4-triazolo[4,3-b]pyridazine derivatives were assessed for their potential as Mcl-1 inhibitors through molecular docking, molecular dynamics (MD) simulations, quantum chemical calculations, and ADMET profiling. Docking identified compounds <b>8f</b>, <b>8j</b>, <b>8k</b>, and <b>8l</b> as promising candidates, with <b>8l</b> exhibiting the most favorable binding free energy (ΔG<sub>bind</sub> = - 58.96 kcal/mol). Docking-derived inhibition constants (<i>Ki</i>) revealed that <b>8f</b>, <b>8j</b>, <b>8k</b>, and <b>8l</b> had <i>Ki</i> values of 0.31 µM, 0.32 µM, 0.35 µM, and 0.34 µM, respectively, while Sunitinib showed a slightly weaker <i>Ki</i> of 0.36 µM. MD simulations demonstrated increased structural stability of the protein-ligand complexes, with RMSD values ranging from 1.68 Å (8f) to 1.90 Å (<b>8j</b>), compared to the unbound APO structure (2.12 Å). Compound <b>8l</b> maintained a low RMSD (1.71 Å) and favorable flexibility profile (RMSF = 0.89 Å), comparable to Sunitinib (RMSF = 0.76 Å). DFT analysis highlighted 8l's high electronic reactivity, with a HOMO-LUMO gap of 3.18 eV in DMF. Although prior experimental studies confirmed <b>8l</b> potent anti-AML activity (IC₅₀ = 1.5 µM), ADMET predictions revealed pharmacokinetic limitations, including low solubility and permeability. These findings position compound <b>8l</b> as a compelling lead candidate for AML therapy and provide a strong foundation for future optimization aimed at improving its pharmacokinetic profile and dynamic stability. To substantiate these computational findings, we will initiate experimental validation studies involving Mcl-1 binding assays and cytotoxicity evaluation in AML cell lines.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-025-00418-1.</p>","PeriodicalId":94038,"journal":{"name":"In silico pharmacology","volume":"13 3","pages":"135"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443659/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting Acute Myeloid Leukemia with 1,2,4-triazolo[4,3-b]pyridazine derivatives: a molecular docking, dynamics, and ADMET approach.\",\"authors\":\"Vincent A Obakachi, Krishna K Govender, Penny P Govender\",\"doi\":\"10.1007/s40203-025-00418-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acute Myeloid Leukemia (AML) remains a critical therapeutic challenge, warranting the development of novel inhibitors targeting essential survival proteins such as Myeloid Cell Leukemia-1 (Mcl-1). In this purely computational study, a series of 1,2,4-triazolo[4,3-b]pyridazine derivatives were assessed for their potential as Mcl-1 inhibitors through molecular docking, molecular dynamics (MD) simulations, quantum chemical calculations, and ADMET profiling. Docking identified compounds <b>8f</b>, <b>8j</b>, <b>8k</b>, and <b>8l</b> as promising candidates, with <b>8l</b> exhibiting the most favorable binding free energy (ΔG<sub>bind</sub> = - 58.96 kcal/mol). Docking-derived inhibition constants (<i>Ki</i>) revealed that <b>8f</b>, <b>8j</b>, <b>8k</b>, and <b>8l</b> had <i>Ki</i> values of 0.31 µM, 0.32 µM, 0.35 µM, and 0.34 µM, respectively, while Sunitinib showed a slightly weaker <i>Ki</i> of 0.36 µM. MD simulations demonstrated increased structural stability of the protein-ligand complexes, with RMSD values ranging from 1.68 Å (8f) to 1.90 Å (<b>8j</b>), compared to the unbound APO structure (2.12 Å). Compound <b>8l</b> maintained a low RMSD (1.71 Å) and favorable flexibility profile (RMSF = 0.89 Å), comparable to Sunitinib (RMSF = 0.76 Å). DFT analysis highlighted 8l's high electronic reactivity, with a HOMO-LUMO gap of 3.18 eV in DMF. Although prior experimental studies confirmed <b>8l</b> potent anti-AML activity (IC₅₀ = 1.5 µM), ADMET predictions revealed pharmacokinetic limitations, including low solubility and permeability. These findings position compound <b>8l</b> as a compelling lead candidate for AML therapy and provide a strong foundation for future optimization aimed at improving its pharmacokinetic profile and dynamic stability. To substantiate these computational findings, we will initiate experimental validation studies involving Mcl-1 binding assays and cytotoxicity evaluation in AML cell lines.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-025-00418-1.</p>\",\"PeriodicalId\":94038,\"journal\":{\"name\":\"In silico pharmacology\",\"volume\":\"13 3\",\"pages\":\"135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443659/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In silico pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40203-025-00418-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In silico pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40203-025-00418-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

急性髓性白血病(AML)仍然是一个关键的治疗挑战,需要开发针对必需生存蛋白(如髓性细胞白血病-1 (Mcl-1))的新型抑制剂。在这项纯计算研究中,通过分子对接、分子动力学(MD)模拟、量子化学计算和ADMET谱分析,评估了一系列1,2,4-三唑[4,3-b]吡嗪衍生物作为Mcl-1抑制剂的潜力。对接发现化合物8f、8j、8k和8l具有较好的结合自由能(ΔGbind = - 58.96 kcal/mol)。停靠衍生抑制常数(Ki)显示,8f、8j、8k和8l的Ki值分别为0.31、0.32、0.35和0.34µM,舒尼替尼的Ki值稍弱,为0.36µM。MD模拟表明,与未结合的APO结构(2.12 Å)相比,蛋白质-配体复合物的结构稳定性增加,RMSD值从1.68 Å (8f)到1.90 Å (8j)。化合物81保持较低的RMSD (1.71 Å)和良好的柔韧性(RMSF = 0.89 Å),与舒尼替尼(RMSF = 0.76 Å)相当。DFT分析表明8l具有较高的电子反应性,在DMF中HOMO-LUMO的间隙为3.18 eV。虽然先前的实验研究证实了8l有效的抗aml活性(IC₅0 = 1.5µM),但ADMET预测显示了药代动力学的局限性,包括低溶解度和渗透性。这些发现将化合物81定位为AML治疗的主要候选药物,并为未来优化其药代动力学特征和动态稳定性提供了坚实的基础。为了证实这些计算结果,我们将在AML细胞系中启动涉及Mcl-1结合测定和细胞毒性评估的实验验证研究。图片摘要:补充资料:在线版本包含补充资料,网址为10.1007/s40203-025-00418-1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting Acute Myeloid Leukemia with 1,2,4-triazolo[4,3-b]pyridazine derivatives: a molecular docking, dynamics, and ADMET approach.

Acute Myeloid Leukemia (AML) remains a critical therapeutic challenge, warranting the development of novel inhibitors targeting essential survival proteins such as Myeloid Cell Leukemia-1 (Mcl-1). In this purely computational study, a series of 1,2,4-triazolo[4,3-b]pyridazine derivatives were assessed for their potential as Mcl-1 inhibitors through molecular docking, molecular dynamics (MD) simulations, quantum chemical calculations, and ADMET profiling. Docking identified compounds 8f, 8j, 8k, and 8l as promising candidates, with 8l exhibiting the most favorable binding free energy (ΔGbind = - 58.96 kcal/mol). Docking-derived inhibition constants (Ki) revealed that 8f, 8j, 8k, and 8l had Ki values of 0.31 µM, 0.32 µM, 0.35 µM, and 0.34 µM, respectively, while Sunitinib showed a slightly weaker Ki of 0.36 µM. MD simulations demonstrated increased structural stability of the protein-ligand complexes, with RMSD values ranging from 1.68 Å (8f) to 1.90 Å (8j), compared to the unbound APO structure (2.12 Å). Compound 8l maintained a low RMSD (1.71 Å) and favorable flexibility profile (RMSF = 0.89 Å), comparable to Sunitinib (RMSF = 0.76 Å). DFT analysis highlighted 8l's high electronic reactivity, with a HOMO-LUMO gap of 3.18 eV in DMF. Although prior experimental studies confirmed 8l potent anti-AML activity (IC₅₀ = 1.5 µM), ADMET predictions revealed pharmacokinetic limitations, including low solubility and permeability. These findings position compound 8l as a compelling lead candidate for AML therapy and provide a strong foundation for future optimization aimed at improving its pharmacokinetic profile and dynamic stability. To substantiate these computational findings, we will initiate experimental validation studies involving Mcl-1 binding assays and cytotoxicity evaluation in AML cell lines.

Graphical abstract:

Supplementary information: The online version contains supplementary material available at 10.1007/s40203-025-00418-1.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信